My ongoing project aims to define the epigenetic alterations leading to drug resistance in Multiple Myeloma patients. More in detail, I’m focusing on the identification of regulatory regions that donate high plasticity to tumor cells, allowing them to escape Bortezomib treatment and re-expand, causing relapses. Thus, the final goal is to define a subset of regions that are strongly modulated in Multiple Myeloma progression and are potential targets for future epigenetic therapies.